At two-year follow-up, Evrysdi continues to show numerical improvements in data, Roche says
A little less than two months after receiving an FDA approval in spinal muscular atrophy, Roche’s Genentech continues to roll out data for risdiplam.
The drug, marketed as Evrysdi in the US, showed improved motor functions in infants as part of a two-year follow-up evaluation from Part 1 of a pivotal trial on which its approval is based. Numerically, there were more patients who could sit without support for five seconds, maintain upright head control, turn themselves over and stand than those at one year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.